Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example EvidenceVariable: CTIS2024-516402-32-00 Primary Outcome 1

Page standards status: Informative

Generated Narrative: EvidenceVariable 346487

version: 2; Last updated: 2025-03-05 19:33:28+0000

url: EvidenceVariable CTIS2024-516402-32-00 Primary Outcome 1

identifier: FEvIR Object Identifier/https://fevir.net/FOI/346487, FEvIR Linking Identifier/CTIS2024-516402-32-00 Primary Outcome 1, CTIS endPoint id/441508, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.24.4

version: 1.0.0-ballot2

name: CTIS2024_516402_32_00_Primary_Outcome_1

title: CTIS2024-516402-32-00 Primary Outcome 1

status: Active

date: 2025-03-27 17:53:24+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

Response to therapy, defined by the absence of any of the following events: i) at 6-month follow-up: persistent renal replacement therapy, eGFR<15ml/mn/1,73m2, or patient death; ii) at W2 : persistent hemolysis despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure.

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Brian S. Alper, MD, MSPH: